Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market

Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market”, which provides insights into oncology sales and price forecasts until 2017. The report also examines the Chinese oncology treatment usage patterns. In addition, the report also includes insights into the oncology R&D pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).

Scope

The scope of this report includes:
- Data and analysis on the oncology market in the China
- Annualized market data for the oncology market from 2002 to 2009, with forecasts to 2017.
- Market data on the therapeutic landscape which covers lung cancer, breast cancer, colorectal cancer, non-hodgkin’s lymphoma and prostate cancer, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The regulatory landscape which covers major regulatory bodies in China, IPR protection, key regulations for conducting oncology research, key government initiatives and pricing and reimbursement scenario
- The competitive landscape of the Chinese oncology market which includes companies such as Roche/Genentech, AstraZeneca, Simcere, Merck and GlaxoSmithKline
- Key M&A activities and Licensing Agreements that took place from 2004 to 2010 in the Chinese oncology market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading countries and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the region’s pharmaceutical market.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships. SHOW LESS READ MORE >

1 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Oncology in China – Introduction 9
2.1 GBI Research Report Guidance 9
3 Oncology in China – Market Characterization 10
3.1 Introduction 10
3.2 Market Size 10
3.3 Annual Cost of Treatment 11
3.4 Treatment Usage Pattern 12
3.4.1 Disease Population 13
3.4.2 Prescription Population 14
3.5 Drivers and Barriers 14
3.5.1 Drivers 14
3.5.2 Restraints 15
4 Oncology in China: Therapeutic Landscape 17
4.1 Introduction 17
4.2 Lung Cancer 18
4.2.1 Market Size 18
4.2.2 Annual Cost of Treatment 19
4.2.3 Treatment Usage Pattern 20
4.2.4 Market Drivers 22
4.2.5 Market Restraints 23
4.3 Breast Cancer 23
4.3.1 Market Size 23
4.3.2 Annual Cost of Treatment 24
4.3.3 Treatment Usage Pattern 25
4.3.4 Market Drivers 27
4.3.5 Market Restraints 28
4.4 Colorectal Cancer 29
4.4.1 Market Size 29
4.4.2 Annual Cost of Treatment 30
4.4.3 Treatment Usage Pattern 31
4.4.4 Market Drivers 33
4.4.5 Market Restraints 33
4.5 Non-Hodgkin’s Lymphoma 34
4.5.1 Market Size 34
4.5.2 Annual Cost of Treatment 35
4.5.3 Treatment Usage Pattern 36
4.5.4 Market Drivers 38
4.5.5 Market Restraints 39
4.6 Prostate Cancer 39
4.6.1 Market Size 39
4.6.2 Annual Cost of Treatment 40
4.6.3 Treatment Usage Pattern 41
4.6.4 Market Drivers 43
4.6.5 Market Restraints 43
5 Oncology in China – Regulatory Landscape 44
5.1 Major Regulatory Bodies in China 44
5.1.1 SFDA (State Food and Drug Administration) 44
5.1.2 CDE (Center for Drug Evaluation) 44
5.1.3 NDRC (National Development and Reform Commission) 45
5.1.4 NICPBP (National Institute for the Control of Pharmaceutical and Biological Products) 46
5.2 IPR Protection in China 46
5.2.1 Patent Law 47
5.2.2 Trademark Law 47
5.2.3 Anti-Unfair Competition Law 48
5.2.4 Regulations on Customs Protection of Intellectual Property Rights 48
5.3 Key Regulations for Conducting Oncology Research in China 49
5.3.1 Drug Administration Law 50
5.3.2 Chinese Clinical Trial Registry 50
5.4 Major Government Initiatives to Support Oncology Research in China 51
5.4.1 OCCP (Office of China Cancer Programs) 51
5.4.2 CSCO (Chinese Society of Clinical Oncology) 51
5.4.3 Chinese Academy of Sciences – Shanghai Institute of Materia Medica 52
5.5 Pricing and Reimbursement 53
5.5.1 Pricing of Drugs in China 53
5.5.2 Reimbursement of Drugs in China 55
5.6 Key Takeaway 57
6 Oncology in China – Pipeline Analysis 58
6.1 Key Area Focused for R&D in China 58
6.1.1 Trend of R&D Investment by Pharmaceutical Players in China 58
6.2 Pipeline Segmentation by Clinical Phase of Development 59
6.3 Pipeline Segmentation by Indication 60
6.3.1 Lung Cancer 60
6.3.2 Breast Cancer 61
6.3.3 Colorectal Cancer 62
6.3.4 Non-Hodgkin’s Lymphoma 63
6.3.5 Prostate Cancer 64
6.4 Key Late Stage Pipeline Drugs 64
6.4.1 Lung Cancer 64
6.4.2 Breast Cancer 66
6.4.3 Colorectal Cancer 68
6.4.4 Non-Hodgkin’s Lymphoma 72
6.4.5 Prostate Cancer 75
6.5 Future Players in Oncology 78
7 Oncology in China – Competitive Landscape 80
7.1 Market Share Analysis 80
7.1.1 Lung Cancer 81
7.1.2 Breast Cancer 82
7.1.3 Colorectal Cancer 83
7.1.4 Non-Hodgkin’s Lymphoma 84
7.1.5 Prostate Cancer 85
7.2 Key Players in the Chinese Oncology Market 86
7.2.1 Roche/Genentech 86
7.2.2 AstraZeneca 90
7.2.3 Simcere 93
7.2.4 GlaxoSmithKline 97
7.2.5 Merck 99
8 Oncology in China – Deals Landscape 104
8.1 Mergers and Acquisitions 104
8.1.1 Deals by Year 104
8.1.2 Deals by Type 105
8.1.3 Deals by Value 106
8.1.4 Deals by Companies 107
8.1.5 Top Five M&A Deals in Oncology in China 107
8.2 Licensing Agreements 110
8.2.1 Deals by Year 110
8.2.2 Deals by Type 111
8.2.3 Deals by Value 112
8.2.4 Deals by Companies 113
8.2.5 Top Five Licensing Deals in Oncology in China 114
9 Appendix 117
9.1 Market Definitions 117
9.2 Abbreviations 117
9.3 Research Methodology 119
9.3.1 Coverage 120
9.3.2 Secondary Research 120
9.3.3 Primary Research 120
9.3.4 Expert Panel Validation 121
9.4 Contact Us 121
9.5 Disclaimer 121
9.6 Sources 121

1.1 List of Tables
Table 1: Oncology in China, Revenue ($m), 2002–2009 10
Table 2: Oncology in China, Revenue Forecast ($m), 2009–2017 11
Table 3: Oncology in China, Annual Cost of Treatment($), 2002–2009 11
Table 4: Oncology in China, Annual Cost of Treatment($), 2009–2017 11
Table 5: Oncology in China, Treatment Usage Pattern (‘000), 2002–2009 12
Table 6: Oncology in China, Treatment Usage Pattern (‘000), 2009–2017 12
Table 7: Lung Cancer, China, Revenue ($m), 2002–2009 18
Table 8: Lung Cancer, China, Revenue Forecast ($m), 2009–2017 18
Table 9: Lung Cancer, China, Annual Cost of Treatment ($), 2002–2009 19
Table 10: Lung Cancer, China, Annual Cost of Treatment ($), 2009–2017 19
Table 11: Lung Cancer, China, Treatment Usage Pattern (‘000), 2002–2009 20
Table 12: Lung Cancer, China, Treatment Usage Pattern (‘000), 2009–2017 20
Table 13: Breast Cancer, China, Revenue ($m), 2002–2009 23
Table 14: Breast Cancer, China, Revenue Forecast ($m), 2009–2017 24
Table 15: Breast Cancer, China, Annual Cost of Treatment ($), 2002–2009 24
Table 16: Breast Cancer, China, Annual Cost of Treatment ($), 2009–2017 24
Table 17: Breast Cancer, China, Treatment Usage Pattern (‘000), 2002–2009 25
Table 18: Breast Cancer, China, Treatment Usage Pattern (‘000), 2009–2017 25
Table 19: Colorectal Cancer, China, Revenue ($m), 2002–2009 29
Table 20: Colorectal Cancer, China, Revenue Forecast ($m), 2009–2017 29
Table 21: Colorectal Cancer, China, Annual Cost of Treatment ($), 2002–2017 30
Table 22: Colorectal Cancer, China, Annual Cost of Treatment ($), 2009–2017 30
Table 23: Colorectal Cancer, China, Treatment Usage Pattern (‘000), 2002–2009 31
Table 24: Colorectal Cancer, China, Treatment Usage Pattern (‘000), 2009–2017 31
Table 25: Non-Hodgkin’s Lymphoma, China, Revenue ($m), 2002–2009 34
Table 26: Non-Hodgkin’s Lymphoma, China, Revenue Forecast ($m), 2009–2017 34
Table 27: Non-Hodgkin’s Lymphoma, China, Annual Cost of Treatment ($), 2002–2009 35
Table 28: Non-Hodgkin’s Lymphoma, China, Annual Cost of Treatment ($), 2009–2017 35
Table 29: Non-Hodgkin’s Lymphoma, China, Treatment Usage Pattern (‘000), 2002–2009 36
Table 30: Non-Hodgkin’s Lymphoma, China, Treatment Usage Pattern (‘000), 2009–2017 36
Table 31: Prostate Cancer, China, Revenue ($m), 2002–2009 39
Table 32: Prostate Cancer, China, Revenue Forecast ($m), 2009–2017 39
Table 33: Prostate Cancer, China, Annual Cost of Treatment($), 2002–2009 40
Table 34: Prostate Cancer, China, Annual Cost of Treatment($), 2009–2017 40
Table 35: Prostate Cancer, China, Treatment Usage Pattern (‘000), 2002–2009 41
Table 36: Prostate Cancer, China, Treatment Usage Pattern (‘000), 2009–2017 41
Table 37: Pharmaceuticals Market, China, Increase in the Per Capita Expenditure for Medical Services in the Urban and Rural Households ($m), 1990–2006 55
Table 38: Oncology in China, Roche/Genentech, Oncology Pipeline, 2010 88
Table 39: Oncology in China, Roche/Genentech, Major Oncology Deals, 2004–2010 88
Table 40: Oncology in China, AstraZeneca, Oncology Pipeline, 2010 92
Table 41: Oncology in China, AstraZeneca, Major Oncology Deals, 2004–2010 92
Table 42: Oncology in China, Simcere, Oncology Pipeline, 2010 94
Table 43: Oncology in China, Simcere, Major Oncology Deals, 2004–2010 95
Table 44: Oncology in China, GlaxoSmithKline, Oncology Pipeline, 2010 98
Table 45: Oncology in China, GlaxoSmithKline, Major Oncology Deals, 2004–2010 98
Table 46: Oncology in China, Merck, Oncology Pipeline, 2010 100
Table 47: Oncology in China, Merck, Major Oncology Deals, 2004–2010 101
Table 48: Oncology in China, AsiaPharm–Solid Success Holdings Acquisition, Key Information 107
Table 49: Oncology in China, Mingyuan Medicare Development – Genetel Acquisition, Key Information 108
Table 50: Oncology in China, Simcere Pharmaceutical – Shandong Simcere Medgenn Bio-Pharmaceutical Acquisition, Key Information 109
Table 51: Oncology in China, Simcere Pharmaceutical–Shanghai Celgen Bio-Pharmaceutical Acquisition, Key Information 109
Table 52: Oncology in China, Undisclosed Company – Jade Pharmaceutical Acquisition, Key Information 109
Table 53: Oncology in China, Licensing Agreements, GlaxoSmithKline - OncoMed Pharmaceuticals, Key Information 114
Table 54: Oncology in China, Licensing Agreements, Takeda-Alnylam Pharmaceuticals, Key Information 114
Table 55: Oncology in China, Licensing Agreements, Celgene-Acceleron Pharma, Key Information 115
Table 56: Oncology in China, Licensing Agreements, Merck-Ariad Pharmaceuticals, Key Information 115
Table 57: Oncology in China, Licensing Agreements, Biogen Idec-PDL BioPharma, Key Information 116

1.2 List of Figures
Figure 1: Oncology in China, Revenue Forecast ($m), 2002–2017 10
Figure 2: Oncology in China, Annual Cost of Treatment ($), 2002–2017 11
Figure 3: Oncology in China, Treatment Usage Pattern, 2002–2017 12
Figure 4: Oncology in China, Prevalence Population, 2002–2017 13
Figure 5: Oncology in China, Prescription Population, 2002–2017 14
Figure 6: Oncology in China, Cancer Mortality Rate, 2008 15
Figure 7: Oncology in China, Sales Value by Indication (%), 2009 and 2017 17
Figure 8: Lung Cancer, China, Revenue Forecast ($m), 2002–2017 18
Figure 9: Lung Cancer, China, Annual Cost of Treatment ($), 2002–2017 19
Figure 10: Lung Cancer, China, Treatment Usage Pattern, 2002–2017 20
Figure 11: Lung Cancer, China, Prevalence Population, 2002–2017 21
Figure 12: Lung Cancer, China, Prescription Population, 2002–2017 22
Figure 13: Breast Cancer, China, Revenue Forecast ($m), 2002–2017 23
Figure 14: Breast Cancer, China, Annual Cost of Treatment ($), 2002–2017 24
Figure 15: Breast Cancer, China, Treatment Usage Pattern, 2002–2017 25
Figure 16: Breast Cancer, China, Prevalence Population, 2002–2017 26
Figure 17: Breast Cancer, China, Prescription Population, 2002–2017 27
Figure 18: Colorectal Cancer, China, Revenue Forecast ($m), 2002–2017 29
Figure 19: Colorectal Cancer, China, Annual Cost of Treatment ($), 2002–2017 30
Figure 20: Colorectal Cancer, China, Treatment Usage Pattern, 2002–2017 31
Figure 21: Colorectal Cancer, China, Prevalence Population, 2002–2017 32
Figure 22: Colorectal Cancer, China, Prescription Population, 2002–2017 32
Figure 23: Non-Hodgkin’s Lymphoma, China, Revenue Forecast ($m), 2002–2017 34
Figure 24: Non-Hodgkin’s Lymphoma, China, Annual Cost of Treatment ($), 2002–2017 35
Figure 25: Non-Hodgkin’s Lymphoma, China, Treatment Usage Pattern, 2002–2017 36
Figure 26: Non-Hodgkin’s Lymphoma, China, Prevalence Population, 2002–2017 37
Figure 27: Non-Hodgkin’s Lymphoma, China, Prescription Population, 2002–2017 38
Figure 28: Prostate Cancer, China, Revenue Forecast ($m), 2002–2017 39
Figure 29: Prostate Cancer, China, Annual Cost of Treatment ($), 2002–2017 40
Figure 30: Prostate Cancer, China, Treatment Usage Pattern, 2002–2017 41
Figure 31: Prostate Cancer, China, Prevalence Population, 2002–2017 42
Figure 32: Prostate Cancer, China, Prescription Population, 2002–2017 43
Figure 33: Oncology in China, Number of Applications Filed and Approved in Center for Drug Evaluation, 2003–2007 45
Figure 34: Oncology in China, Clinical Trials Approval Process, 2010 49
Figure 35: Oncology in China, Pricing and Reimbursement of Drugs 53
Figure 36: Oncology in China, Drug Pricing Criteria, 2010 54
Figure 37: Pharmaceuticals Market, China, Increase in the Per Capita Expenditure for Medical Services in the Urban and Rural Households ($m), 1990–2006 55
Figure 38: Pharmaceuticals Market, China, Number of Drugs in National Reimbursement Drug List, 2004 and 2009 56
Figure 39: Oncology in China, Global Pipeline by Phase of Development (%), 2010 59
Figure 40: Oncology in China, Global Pipeline by Indication (%), 2010 60
Figure 41: Oncology in China, Lung Cancer, Global Pipeline by Phase of Development (%), 2010 60
Figure 42: Oncology in China, Breast Cancer, Global Pipeline by Phase of Development (%), 2010 61
Figure 43: Oncology in China, Colorectal Cancer, Global Pipeline by Phase of Development (%), 2010 62
Figure 44: Oncology in China, Non-Hodgkin’s Lymphoma, Global Pipeline by Phase of Development (%), 2010 63
Figure 45: Oncology in China, Prostate Cancer, Global Pipeline by Phase of Development (%), 2010 64
Figure 46: Oncology in China, Future Players in Global Oncology Market, 2010 78
Figure 47: Oncology in China, Pipeline by Cancer Type for Future Players in Global Oncology Market, 2010 79
Figure 48: Oncology in China, Market Share of Top Companies (%), 2009 80
Figure 49: Oncology in China, Lung Cancer, Market Share of Top Companies (%), 2009 81
Figure 50: Oncology in China, Breast Cancer, Market Share of Top Companies (%), 2009 82
Figure 51: Oncology in China, Colorectal Cancer, Market Share of Top Companies (%), 2009 83
Figure 52: Oncology in China, Non-Hodgkin’s Lymphoma, Market Share of Top Companies (%), 2009 84
Figure 53: Oncology in China, Prostate Cancer, Market Share of Top Companies (%), 2009 85
Figure 54: Oncology in China, Roche CEO Statement on Roche’s Investments in China, September 2009 86
Figure 55: Oncology in China, SWOT Analysis – Roche, 2010 90
Figure 56: Oncology in China, SWOT Analysis – AstraZeneca, 2010 93
Figure 57: Oncology in China, SWOT Analysis – Simcere, 2010 96
Figure 58: Oncology in China, SWOT Analysis – GlaxoSmithKline, 2010 99
Figure 59: Oncology in China, SWOT Analysis – Merck, 2010 103
Figure 60: Oncology in China, M&A Deals (Number and Value) by Year, 2005–2010 104
Figure 61: Oncology in China, M&A Deals by Type, (%). 2005–2010 105
Figure 62: Oncology in China, M&A Deals by Value, (%). 2005–2010 106
Figure 63: Oncology in China, M&A Deals by Companies, $m. 2005–2010 107
Figure 64: AsiaPharm – Solid Success Holdings Acquisition, AsiaPharm Executive Chairman Statement on the Purpose of Acquisition 108
Figure 65: Radient Pharmaceuticals – Jade Pharmaceutical Divestment, Radient Pharmaceuticals CEO Statement on the Purpose of Divestment 110
Figure 66: Oncology in China, Licensing Agreements, Deals by Year, 2004–2010 110
Figure 67: Oncology in China, Licensing Agreements, Deals by Type, 2004–2010 111
Figure 68: Oncology in China, Licensing Agreements, Deals by Value, 2004–2010 112
Figure 69: Oncology in China, Licensing Agreements, Deals by Companies, 2004–2010 113

“Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market”, which provides insights into oncology sales and price forecasts in China until 2017. The report also examines Chinese oncology treatment usage patterns. In addition, the report also includes insights into the oncology Research and Development (R&D) pipeline. The report provides an in-depth analysis of the top five oncology therapeutic indications, which are breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL).

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Oncology Market in China is Expected to Witness a High Growth Rate Driven by Growing Cancer Prevalence and Better Drug Access

The oncology market in China is estimated to reach $2.2 billion in 2017 from $830m in 2009, indicating a CAGR (Compound Annual Growth Rate) of 12.9% between 2009 and 2017. The major drivers of this growth will be the increasing prevalence population for major cancer indications, increased use of chemotherapy drugs, increasing rate of urbanization and high unmet need in terms of safer and more efficacious medicines.

However, the dominance of generics in the local oncology market, the low level of reimbursements for Western, branded pharmaceutical drugs as well as the nuisance of counterfeit drugs are expected to be some of the biggest challenges facing big pharmaceutical companies attempting to establish themselves in the Chinese oncology market.

The Top Five Companies in China’s Oncology Market Account for Less than 30% of Market Share

The competition in the cancer therapeutics market in China is largely dominated by the big pharmaceutical companies of the US and Europe. However, the market is highly fragmented, with the top five players occupying only 29% of the entire market. There is only one Chinese company, Simcere, which found a place in the top five players, with 5% of the market share, third highest after Roche/Genentech and AstraZeneca. This represents substantial scope for Mergers and Acquisitions (M&A) to improve the competitive positions of the leading players in the market.

However, a noteworthy aspect of the competitive landscape is the next five major players in the market, which includes three Chinese companies (Sichuan Jiufeng, Jiangsu LYG Hengrui Pharma and Shanghai Jinhe Biotechnology Company Ltd.) and a Japanese company (Symbio Pharmaceuticals), as well as European company Sanofi-aventis.

Going forward, the competition in the branded oncology drugs market is expected to increase as the Chinese pharmaceutical market opens up to patented drugs. In addition, the growth in the overall oncology market is also expected to attract other major pharmaceutical companies to China.